Radiopharm Theranostics (RADX) Equity Average (2025)
Radiopharm Theranostics (RADX) has disclosed Equity Average for 1 consecutive years, with $35.1 million as the latest value for Q2 2025.
- On a quarterly basis, Equity Average changed N/A to $35.1 million in Q2 2025 year-over-year; TTM through Jun 2025 was $35.1 million, a N/A change, with the full-year FY2025 number at $35.1 million, down 3.71% from a year prior.
- Equity Average was $35.1 million for Q2 2025 at Radiopharm Theranostics.
- In the past five years, Equity Average ranged from a high of $35.1 million in Q2 2025 to a low of $35.1 million in Q2 2025.